Rice Hall James & Associates LLC Sells 1,356 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Rice Hall James & Associates LLC decreased its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 103,127 shares of the company’s stock after selling 1,356 shares during the quarter. Medpace accounts for 1.8% of Rice Hall James & Associates LLC’s portfolio, making the stock its 11th biggest holding. Rice Hall James & Associates LLC owned approximately 0.36% of Medpace worth $31,422,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the company. Oxbow Advisors LLC bought a new stake in Medpace in the 1st quarter worth approximately $2,701,000. Joseph Group Capital Management increased its stake in Medpace by 15.3% in the 1st quarter. Joseph Group Capital Management now owns 4,173 shares of the company’s stock worth $1,271,000 after acquiring an additional 553 shares during the last quarter. Covey Capital Advisors LLC bought a new stake in Medpace in the 1st quarter worth approximately $1,261,000. Alps Advisors Inc. increased its stake in Medpace by 10.0% in the 1st quarter. Alps Advisors Inc. now owns 1,098 shares of the company’s stock worth $335,000 after acquiring an additional 100 shares during the last quarter. Finally, Linden Thomas Advisory Services LLC increased its position in shares of Medpace by 1.9% during the 1st quarter. Linden Thomas Advisory Services LLC now owns 4,746 shares of the company’s stock valued at $1,446,000 after purchasing an additional 87 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on MEDP. Truist Financial cut their target price on Medpace from $333.00 to $300.00 and set a “hold” rating on the stock in a research report on Wednesday, April 23rd. William Blair reissued a “market perform” rating on shares of Medpace in a research report on Tuesday, April 22nd. TD Cowen downgraded Medpace from a “buy” rating to a “hold” rating and cut their target price for the company from $370.00 to $328.00 in a research report on Monday, April 14th. Leerink Partners began coverage on Medpace in a research report on Monday, March 24th. They set a “market perform” rating and a $330.00 target price on the stock. Finally, Leerink Partnrs raised Medpace to a “hold” rating in a research report on Monday, March 24th. Twelve equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $344.82.

Medpace Stock Down 1.4%

MEDP opened at $323.50 on Monday. The business has a fifty day moving average of $305.61 and a 200 day moving average of $318.52. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $459.77. The stock has a market cap of $9.30 billion, a P/E ratio of 24.69, a PEG ratio of 5.85 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $3.06 by $0.61. Medpace had a return on equity of 54.36% and a net margin of 19.31%. The business had revenue of $558.57 million during the quarter, compared to analysts’ expectations of $528.38 million. During the same period in the prior year, the business earned $3.20 EPS. Equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Buying and Selling at Medpace

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the company’s stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the sale, the director directly owned 2,998 shares in the company, valued at approximately $904,856.36. This represents a 36.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 20.30% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.